T1	Participants 75 122	children and adolescents with autistic disorder
T2	Participants 276 324	children and adolescents with autistic disorders
T3	Participants 394 494	patients (5-17 years of age, who completed the previous fixed-dose, 6 week, double-blind [DB] phase)
T4	Participants 779 840	Fifty-six (71%) out of 79 enrolled patients completed the OLE
